RARA CRAFT DATABASE for FDA Medical Devices
PMAP210040

FDA DEVICE FACTS

RESOLUTION ctDx FIRST

Exact Sciences Corporation

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEDecember 12, 2022PRODUCT CODEPQP

Indications for use

The Agilent Resolution ctDx FIRST assay is a qualitative next generation sequencing-based, in vitro diagnostic test that uses targeted hybrid-capture sequencing technology to detect and report single nucleotide variants (SNVs) and deletions in two genes. The Agilent Resolution ctDx FIRST assay utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). The test is intended as a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who may benefit from treatment with the targeted therapy listed in Table 1, in accordance with the approved therapeutic labeling. Table 1. Companion Diagnostic Indication Indication Biomarker Therapy Non-small cell lung cancer (NSCLC) KRAS G12C KRAZATI™ (adagrasib) A negative result from a plasma specimen does not assure that the patient’s tumor is negative for genomic findings. Patients with NSCLC who are negative for the biomarker listed in Table 1 should be reflexed to tissue biopsy testing for Table 1 biomarker using an FDA-approved tumor tissue test, if feasible. Additionally, the test is intended to provide tumor mutation profiling for SNVs and deletions in the EGFR gene for use by qualified health care professionals in accordance with professional guidelines in oncology for patients with NSCLC. The test is for use

with patients previously diagnosed with NSCLC and in conjunction with other laboratory and clinical findings. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. The Agilent Resolution ctDx FIRST assay is a single-site assay performed at Resolution Bioscience, Inc.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026